Pfizer/BioNTech: Trials of vaccine that treats up to the BA.2 Omicron subvariant

- Article Top Advertisement -

Pfizer Inc and BioNTech SE announced today that they have initiated mid-level trials of a modified Covid-19 vaccine that targets both the original variants and the BA.2 Omicron sub-variant.

The vaccine is in an initial proof-of-concept study to gather more data (

- Article Inline Advertisement 1-

The BA.4 and BA.5 subvariants combined are estimated to account for nearly 95% of the subvariants in circulation in the United States in the week ending July 23.

The US Food and Drug Administration last month asked companies to make vaccines that target the BA.4 and BA.5 subvariants, which are currently the dominant ones, for a possible booster in the fall.

- Advertisement -

Source: RES-MPE

Source: Capital

- Article Bottom Advertisement -


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles